<DOC>
	<DOC>NCT01743469</DOC>
	<brief_summary>This is an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma (Cohort H), ovarian carcinoma (Cohort O), renal cell carcinoma (Cohort R) and gastric carcinoma (Cohort G) who have progressed after standard therapies.</brief_summary>
	<brief_title>A Study With Tasquinimod Treating Patients in Four Independent Cohorts of Hepatocellular, Ovarian, Renal Cell and Gastric Cancers</brief_title>
	<detailed_description>The clinical activity of tasquinimod will be evaluated independently in each individual cohort of patients of the four different tumour types, namely Cohort H, Cohort O, Cohort R and Cohort G respectively.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Histologically confirmed metastatic or advanced hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage C or B not amenable to locoregional therapy or refractory to locoregional therapy, ChildPugh A, previously treated by sorafenib Histologically confirmed metastatic or advanced ovarian epithelial, fallopian tube or primary peritoneal cavity cancer, progression within 6 months of a platinum containing chemotherapy regimen Histologically confirmed metastatic renal cell cancer, previously treated with at least one vascular endothelial growth factor (VEGF) inhibitor, at most two prior targeted therapies Histologically confirmed metastatic or advanced gastric cancer after one line of chemotherapy containing platinum and fluoropyrimidine Other primary malignancy within the past 3 years (except for fully resected non melanoma skin cancer, localised prostate cancer with normal prostate specific antigen level, or cervical cancer in situ) Malabsorption (other than in Cohort G patients and partial or complete gastrectomy) or intestinal obstruction History of pancreatitis History of myocardial infarction, unstable angina, congestive heart failure New York Heart Association class III/IV, cerebrovascular accident, transient ischaemic attack, limb claudication at rest in the previous 6 months, or ongoing symptomatic dysrhythmias, or uncontrolled atrial, or ventricular arrhythmias, or uncontrolled hypertension defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>